-transparent.png){kind=logo}
Therapy for cystic fibrosis (CF) has progressed during the past several decades. Much of this progress is because of advances in genetic testing to precisely identify the underlying cause of CF transmembrane regulator (CFTR) dysfunction. However, with more than 1900 mutations that can produce a faulty CFTR, the management of CF can remain a challenge. Several innovative drugs recently approved by the Food and Drug Administration, termed genetic modulators, target the underlying disease by modulating the CFTR defect. This review provides physicians with an established simple classification scheme to guide their use of these drugs. The treatment challenge of 1900 CFTR mutations has been simplified into 6 physiologic classes, each paired with an available therapy to offer patients the most functional improvement. Drug therapy monitoring, adverse effects, and indications for discontinuation must also be considered.
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
January 2006,
Molecular diagnosis & therapy,
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
July 2023,
Annals of internal medicine,
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
January 2012,
PloS one,
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
January 2013,
The journal of gene medicine,
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
March 2022,
Internal medicine journal,
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
April 2020,
Pharmaceuticals (Basel, Switzerland),
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
May 1992,
Neuron,
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
August 2015,
Therapeutic advances in respiratory disease,
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
May 1998,
Human genetics,
Deborah Virant-Young, and
Justin Thomas, and
Sarah Woiderski, and
Michelle Powers, and
Joseph Carlier, and
James McCarty, and
Tyler Kupchick, and
Anthony Larder
October 1992,
British medical bulletin,
